Drug intelligence / Profile preview

NELL-1 + DBX

Development stage
Unknown
Lead developer
Bone Biologics
Modality
Recombinant Proteins and Enzymes
Administration
Topical (surgically Implanted At The Site Of Bone Or Spinal Fusion)
01

Overview

**NELL-1 + DBX** is a combination product consisting of recombinant human NELL-1 (a protein growth factor with osteogenic activity) formulated together with **DBX**, a proprietary demineralized bone matrix (DBM) carrier. NELL-1 is an osteoblast-specific growth factor that promotes bone formation by upregulating osteoblast function, inhibiting osteoclasts, and activating Wnt/β-catenin signaling pathways. DBX serves both as an osteoconductive scaffold and as a delivery vehicle, providing physical support for new bone formation as well as controlled release of NELL-1 at the site of implantation. The primary clinical indication is for enhancement of spinal fusion, with preclinical and clinical studies focused on degenerative disc disease and spinal fusion surgery. The product is mechanistically distinct from bone morphogenetic proteins (BMPs), with improved specificity and potentially fewer adverse effects. Development is led by Bone Biologics; DBX is manufactured by Musculoskeletal Transplant Foundation.

Brand names
NB1NB-1NB 1
Other names
NELL-1/DBXrecombinant human NELL-1 with DBXNELL-1 plus demineralized bone matrixNELL1 plus demineralized bone matrixNELL 1 plus demineralized bone matrix
02

Targets

HSPG (Basement membrane-specific heparan sulfate proteoglycan core protein (perlecan))CNTNAP4 (Contactin-associated protein-like 4)α3β1 (Integrin alpha 3 beta 1)

Beyond the preview

Go deeper on NELL-1 + DBX.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on NELL-1 + DBX.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call